Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice

Non-alcoholic steatohepatitis (NASH) has no approved therapy. The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. Therefore, the present study aimed to investigate the effects and underlying mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen-Cong, Zhao, Su-Xian, Ren, Wei-Guang, Zhang, Yu-Guo, Wang, Rong-Qi, Kong, Ling-Bo, Zhang, Qing-Shan, Nan, Yue-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200799/
https://www.ncbi.nlm.nih.gov/pubmed/34149876
http://dx.doi.org/10.3892/etm.2021.10262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200799/
https://www.ncbi.nlm.nih.gov/pubmed/34149876
http://dx.doi.org/10.3892/etm.2021.10262

Ejemplares similares